Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Change in Receivables (2018 - 2025)

Wave Life Sciences (WVE) has disclosed Change in Receivables for 7 consecutive years, with -$8.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 713.5% year-over-year to -$8.7 million, compared with a TTM value of -$146000.0 through Dec 2025, up 99.26%, and an annual FY2025 reading of -$146000.0, up 99.26% over the prior year.
  • Change in Receivables was -$8.7 million for Q4 2025 at Wave Life Sciences, down from $8.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $14.1 million in Q4 2023 and bottomed at -$37.5 million in Q3 2021.
  • Average Change in Receivables over 4 years is -$4.9 million, with a median of $0.0 recorded in 2024.
  • Peak annual rise in Change in Receivables hit 749.84% in 2025, while the deepest fall reached 713.5% in 2025.
  • Year by year, Change in Receivables stood at -$22.5 million in 2021, then skyrocketed by 162.6% to $14.1 million in 2023, then tumbled by 89.9% to $1.4 million in 2024, then plummeted by 713.5% to -$8.7 million in 2025.
  • Business Quant data shows Change in Receivables for WVE at -$8.7 million in Q4 2025, $8.4 million in Q3 2025, and $1.6 million in Q2 2025.